Expression of Pax5 gene in human haematopoietic cells and tissues: Comparison with immunodeficient donors

Clinical and Experimental Immunology

Volumn 111, Issue 2, 1998, Pages 339-344

  Kaneko, H ^a   Ariyasu, T ^b   Inoue, R ^a   Fukao, T ^a   Kasahara, K ^a   Teramoto, T ^a   Matsui, E ^a   Hayakawa, S ^a   Kondo, N ^a  

^a GIFU UNIVERSITY   (Japan)

^b HAYASHIBARA BIOCHEMICAL LABORATORIES INC   (Japan)

Author keywords

CD19; CD40; Common variable immunodeficiency; Pax5; RT PCR

Indexed keywords

CD19 ANTIGEN; CD40 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2; MONOCLONAL ANTIBODY; TRANSCRIPTION FACTOR;

ADOLESCENT; ADULT; ARTICLE; B LYMPHOCYTE DIFFERENTIATION; BONE MARROW; CHILD; COMMON VARIABLE IMMUNODEFICIENCY; CONTROLLED STUDY; FEMALE; FETUS; FETUS LIVER; GENE EXPRESSION; HEMATOPOIETIC CELL; HEMATOPOIETIC TISSUE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; ORGAN DONOR; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; SPLEEN;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; B-CELL-SPECIFIC ACTIVATOR PROTEIN; B-LYMPHOCYTES; CELL DIFFERENTIATION; CELL LINE; CHILD; CHILD, PRESCHOOL; COMMON VARIABLE IMMUNODEFICIENCY; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HEMATOPOIETIC STEM CELLS; HUMANS; INTERLEUKIN-10; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MALE; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; STIMULATION, CHEMICAL; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 0031909994     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1998.00509.x     Document Type: Article

References (41)

1. Adams B, Dorfler P, Aguzzi A, Kozmik Z, Urbanek P, Maurer-Fogy I, Busslinger M. Pax-5 encodes the transcriptional factor BSAP and is expressed in B lymphocytes, the developing CNS, and adults testis. Genes Dev 1992; 6:1589-607.
2. Kozmik Z, Wang S, Dorfler P, Adams B, Busslinger M. The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP. Mol Cell Biol 1992; 12:2662-72.
3. Okabe T, Watanabe T, Kudo A. A pre-B- and B cell-specific DNA-binding protein, EBB-1, which binds to the promoter of the VpreB1 gene. Eur J Immunol 1992; 22:37-43.
4. Zwollo P, Desiderio S. Specific recognition of the blk promoter by the B-lymphoid transcription factor B-cell-specific activator protein. J Biol Chem 1994; 269:15310-7.
5. Rothman P, Li SC, Gorham B, Glimcher L, Alt F, Boothby M. Identification of a conserved lipopolysaccharide-plus -interleukin-4-responsive element located at the promoter of germ line ε transcripts. Mol Cell Biol 1991; 11:5551-61.
6. Liao F, Giannini SL, Birshtein BK. A nuclear DNA-binding protein expressed during early stages of B cell differentiation interacts with diverse segments within and 3′ of the IgH chain gene cluster. J Immunol 1992; 148:2909-17.
7. Singh M, Birshtein K. NF-HB (BSAP) is a repressor of the murine immunoglobulin heavy-chain 3′α enhancer at early stage of B-cell differentiation. Mol Cell Biol 1993; 13:3611-22.
8. Neurath MF, Strober W, Wakatsuki Y. The murine Ig3′α enhancer is a target site with repressor function for B cell lineage-specific transcription factor BSAP (NF-HB, Sα-BP). J Immunol 1994; 153:730-42.
9. Wakatsuki YW, Neurath MF, Max EE, Strober W. The B cell-specific transcription factor BSAP regulates B cell proliferation. J Exp Med 1994; 179:1099-108.
10. Urbanek P, Wang ZQ, Fetka I, Wagner EF, Busslinger M. Complete block of early B cell differentiation and altered patterning of the posterior midbrain in mice lacking Pax5/BSAP. Cell 1994; 79:901-12.
11. Neurath MF, Stuber ER, Strober W. BSAP: a key regulator of B-cell development and differentiation. Immunol Today 1995; 16:564-9.
12. Shivdasani RA, Orkin SH. The transcriptional control of hematopoiesis. Blood 1996; 87:4025-39.
13. Michaelson JS, Singh M, Birshten BK. B cell lineage-specific activator protein (BSAP) a player at multiple stages of B cell development. J Immunol 1996; 156:2349-51.
14. Kaneko H, Kondo N, Motoyoshi F, Mori S, Kobayashi Y, Inoue Y, Orii T. Expression of immunoglobulin genes in common variable immunodeficiency. J Clin Immunol 1991; 11:262-7.
15. Ariyasu T, Kimura N, Kikuchi M, Kohno K, Sugamura K, Watanabe T, Minowada J. Induced natural killer -like cytotoxic function in the TCR δ-1 positive human leukemic T-cell lines. Leukemia 1991; 5:807-12.
16. Lazarus H, Barell EF, Krishan A, Livingston DM, Harris K, Schlossman SF, Chess L. Characterization of a unique cell line (LAZ 221) from human acute lymphocytic ("null" cell) leukemia. Cancer Res 1978; 38:1362-7.
17. Minowada J, Tsubota T, Greaves MF, Walters TR. A non-T, non-B human leukemia cell line (NALM-1); establishment of the cell line and presence of leukemia-associated antigens. J Natl Cancer Inst 1977; 59:83-7.
18. Han T, Minowada J. Use of stimulating capacity of mixed lymphocyte reaction (MLR-S) as a possible marker for the cell-origin of null-cell acute lymphoblastic leukaemia. Immunology 1978; 35:333-9.
19. Vallera DA, Quinones RR, Azemove SM, Soderling CC. Monoclonal antibody-toxin conjugates reactive against human T lymphocytes. A comparison of antibody linked to intact ricin toxin with antibody linked to ricin A chain. Transplantation 1984; 37:387-92.
20. Matsuo Y, Ariyasu T, Adachi T, Tsubota T, Imanishi J, Minowada J. Establishment and characterization of a bi-phenotypic leukemic cell line, NALM-19, from a patient with acute leukemia. Hum Cell 1991; 4:257-60.
21. Matsuo Y, Ariyasu T, Ohmoto E, Kimura I, Minowada J. Bi-phenotypic t(9;22)-positive leukemia cell lines from a patient with acute leukemia: NALM-20, established at the onset: and NALM-21, NALM-22 and NALM-23, established after relapse. Hum Cell 1991; 4:335-8.
22. Krueger RG, Staneck LD, Boehlecke JM. Tumor-associated antigens in human myeloma. J Natl Cancer Inst 1976; 56:711-5.
23. Han T, Dadey B, Minowada J, Golde DW. Human myeloma cells and their strong stimulating capacity in 'one-way' mixed lymphocyte reaction: a comparative study with leukaemic B lymphoid cells. Immunology 1979; 38:63-8.
24. Seon BK, Negoro S, Barcos MP, Tebbi CK, Chervinsky D, Fukukawa T. Monoclonal antibody SN2 defining a human T cell leukemia-associated cell surface glycoprotein. J Immunol 1984; 132:2089-95.
25. Morikawa S, Tatsumi E, Baba M, Harada T, Yasuhira K. Two E-rosette-forming lymphoid cell lines. Int J Cancer 1978; 21:166-70.
26. Koeffler HP, Lowe L, Golde DW. Amygdalin (Laetrile): effect on clonogenic cells from human myeloid leukemia cell lines and normal human marrow. Cancer Treat Rep 1980; 64:105-9.
27. Breitman TR, Selonick SE, Collins SJ. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA 1980; 77:2936-40.
28. Matsuo Y, Adachi T, Tsubota T, Imanishi J, Minowada J. Establishment and characterization of a novel megakaryoblastic cell line, MOLM-1, from a patient with chronic myelogenous leukemia. Hum Cell 1991; 4:261-4.
29. Hashimoto S, Tsukada S, Matsushita M et al. Identification of Bruton's tyrosine kinase (Btk) gene mutations and characterization of derived proteins in 35 X-linked agammaglobulinemia families: a nationwide study of Btk deficiency in Japan. Blood 1996; 88:561-73.
30. Arpin C, Dechanet J, Kooten CV, Merville P, Grouard G, Briere F, Banchereau J, Liu YF. Generation of memory B cells and plasma cells in vitro. Science 1995; 268:720-2.
31. Fuleihan R, Ahern D, Geha RS. Decreased expression of the ligand for CD40 in newborn lymphocytes. Eur J Immunol 1994; 24:1925-8.
32. + T cells from normal and immunodeficient donors using directly conjugated anti-cytokine antibodies and three-colour flow cytometry. Clin Exp Immunol 1996; 105:517-22.
33. Ferrer JM, Iglesias J, Hernandez M, Matamoros N. Alternations in interleukin secretion (IL-2 and IL-4) by CD4 and CD4 CD45RO cells from common variable immunodeficiency (CVI) patients. Clin Exp Immunol 1995; 102:286-9.
34. Eisenstein EM, Chua K, Strober W. B cell differentiation defects in common variable immunodeficiency are ameliorated after stimulation with anti-CD40 antibody and IL10. J Immunol 1994; 152:5957-68.
35. + T cells. Clin Exp Immunol 1995; 101:82-8.
36. Vorechovsky I, Koskinen S, Paganelli R, Smith CIE, Busslinger M, Hammarstrom L. The Pax5 gene: a linkage and mutation analysis in candidate human primary immunodeficiency. Immunogenetics 1995; 42:149-52.
37. Meffre E, LeDeist F, de Saint-Basile G, Deville A, Fougereau M. Fischer A, Schiff C. A human non-XLA immunodeficiency disease characterized by blockage of B cell development at an early proB cell stage. J Clin Invest 1996; 98:1519-26.
38. Baldwin CT, Hoth CF, Amos JA, da-Silva EO, Milunsky A. An exonic mutation in the HuP2 paired domain gene causes Waardenburg's syndrome. Nature 1992; 355:637-8.
39. Tassabehji M, Read AP, Newton VE, Harris R, Balling R, Gruss P, Strachan T. Waardenburg's syndrome patients have mutations in the human homologue of Pax-3 paired box gene. Nature 1992; 355:635-6.
40. Mahmoud MS, Huang N, Nobuyoshi M, Lisukov IA, Tanaka H, Kawano MM. Altered expression of Pax-5 gene in human myeloma cells. Blood 1996; 87:4311-5.
41. Iida S, Rao PH, Nallasivam P et al. The t(9;14)(p13;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the Pax-5 gene. Blood 1996; 88:4110-7.